| Title |
Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
|
|---|---|
| Published in |
American Journal of Cardiovascular Drugs, October 2014
|
| DOI | 10.1007/s40256-014-0092-1 |
| Pubmed ID | |
| Authors |
Talitha I. Verhoef, William K. Redekop, Fazila Hasrat, Anthonius de Boer, Anke Hilse Maitland-van der Zee |
| Abstract |
Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in patients with atrial fibrillation in a country with specialized anticoagulation clinics (the Netherlands) and in a country without these clinics (the UK). |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | <1% |
| Colombia | 1 | <1% |
| Slovenia | 1 | <1% |
| Unknown | 105 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 22 | 20% |
| Researcher | 16 | 15% |
| Student > Bachelor | 13 | 12% |
| Student > Ph. D. Student | 11 | 10% |
| Other | 7 | 6% |
| Other | 21 | 19% |
| Unknown | 18 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 20% |
| Economics, Econometrics and Finance | 5 | 5% |
| Nursing and Health Professions | 4 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Other | 7 | 6% |
| Unknown | 23 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2021.
All research outputs
#5,593,114
of 22,768,097 outputs
Outputs from American Journal of Cardiovascular Drugs
#115
of 425 outputs
Outputs of similar age
#60,400
of 258,576 outputs
Outputs of similar age from American Journal of Cardiovascular Drugs
#1
of 7 outputs
Altmetric has tracked 22,768,097 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 425 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,576 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them